Methods and materials for assessing and treating neurologic autoimmune disorders and/or cancer
AssigneeMayo Foundation for Medical Education and Research
InventorsAnastasia Zekeridou, Vanda A. Lennon, Sean J. Pittock, Binxia Yang, Eoin P. Flanagan
Life of this patent
Estimating the term…
Abstract
This document relates to methods and materials involved in assessing and/or treating mammals having a neurological autoimmune disorder (e.g., a paraneoplastic neurological autoimmune disorder) and/or cancer. For example, methods and materials for detecting anti-neuronal nuclear antibody type 3 (ANNA3) antibodies are provided.
Claims21
A method for detecting an anti-neuronal nuclear antibody type 3 (ANNA3) autoantibody in a sample, wherein said method comprises:
- (a) contacting said sample with a composition comprising a Dachshund homolog 1 (DACH1) polypeptide, wherein at least 5 percent of the polypeptide content of said composition is said DACH1 polypeptide to form an ANNA3 autoantibody-DACH1 polypeptide complex if said sample comprises said ANNA3 autoantibody;
- and
- (b) detecting the presence or absence of said complex, wherein the presence of said complex indicates that said sample contains said ANNA3 autoantibody, and wherein the absence of said complex indicates that said sample lacks said ANNA3 autoantibody.
A method for detecting an ANNA3 autoantibody in a sample, wherein said method comprises:
- (a) contacting said sample with a fragment of a DACH1 polypeptide to form an ANNA3 autoantibody-fragment complex if said sample comprises said ANNA3 autoantibody;
- and
- (b) detecting the presence or absence of said complex, wherein the presence of said complex indicates that said sample contains said ANNA3 autoantibody, and wherein the absence of said complex indicates that said sample lacks said ANNA3 autoantibody.
A method for assessing a mammal having an autoimmune neurological disorder, wherein said method comprises:
- (a) determining the presence or absence of an ANNA3 autoantibody in a sample obtained from said mammal, wherein said determining comprises:
- (i) contacting said sample with a composition comprising a DACH1 polypeptide, wherein at least 5 percent of the polypeptide content of said composition is said DACH1 polypeptide to form an ANNA3 autoantibody-DACH1 polypeptide complex if said sample comprises said ANNA3 autoantibody, and
- (ii) detecting the presence or absence of said complex;
- (b) classifying said mammal as having an ANNA3-positive autoimmune neurological disorder if said complex is present;
- and
- (c) classifying said mammal as having an ANNA3-negative autoimmune neurological disorder if said complex is absent.
13-19. (canceled)
A method for treating a mammal having an autoimmune neurological disorder, wherein said method comprises:
- (a) determining the presence of an ANNA3 autoantibody in a sample obtained from said mammal, wherein said determining comprises:
- (i) contacting said sample with a composition comprising a DACH1 polypeptide, wherein at least 5 percent of the polypeptide content of said composition is said DACH1 polypeptide to form an ANNA3 autoantibody-DACH1 polypeptide complex if said sample comprises said ANNA3 autoantibody, and
- (ii) detecting the presence of said complex, and
- (b) administering an immunosuppressant to said mammal.
A method for treating a mammal having an autoimmune neurological disorder, wherein said method comprises:
- (a) determining the presence of an ANNA3 autoantibody in a sample obtained from said mammal, wherein said determining comprises:
- (i) contacting said sample with a fragment of a DACH1 polypeptide to form an ANNA3 autoantibody-fragment complex if said sample comprises said ANNA3 autoantibody, and
- (ii) detecting the presence of said complex;
- and
- (b) administering an immunosuppressant to said mammal.
Dependencies are inferred from the claim text.